-

$undefined

N/A

(N/A)

bluebird bio NASDAQ:BLUE bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

Location: | Website: www.bluebirdbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

346.9M

Cash

144.1M

Avg Qtr Burn

-61.28M

Short % of Float

25.60%

Insider Ownership

0.54%

Institutional Own.

43.90%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZYNTEGLO (beti-cel) Details Beta thalessemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SKYSONA (eli-cel) (Lenti-D) Details cerebral adrenoleukodystrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYFGENIA (Lovo-cel) (LentiGlobin) (bb1111) Details Sickle cell disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABECMA (ide-cel) (bb2121) Details Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lovo-cel Details Sickle cell disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.